Back to results
US 2026/0063650 A1Published application
Method for excluding factor xia inhibitors in patient samples
AssigneeSiemens Healthcare Diagnostics Products GmbH
InventorsChrista DUWE, Norbert Zander, Katharina Naumann
Life of this patent
Estimating the term…
Abstract
The present disclosure is in the field of coagulation diagnostics and relates to a method for excluding anticoagulants from the group of factor XIa inhibitors in a patient sample.
Claims17
A method for excluding an anticoagulant from the group of a factor XIa inhibitors in a patient sample, the method comprising the steps of:
- a) preparing a first reaction mixture containing the patient sample and a second reaction mixture containing a normal plasma sample by mixing each of the patient sample and the plasma sample with
- i) a factor XI-deficient plasma, and
- ii) at least one neutralizing substance which neutralizes an anticoagulant other than an anticoagulant from the group of factor XIa inhibitors, and
- iii) a coagulation activator of the intrinsic blood coagulation system;
- b) measuring a first coagulation time in the first reaction mixture (APTT XISample) and a second coagulation time in the second reaction mixture (APTT XINormal);
- c) forming a quotient APTT XISample/APTT XINormal from the first and the second coagulation times;
- d) comparing the quotient with a predetermined reference value;
- and
- e) excluding anticoagulants from the group of factor XIa inhibitors in the patient sample if the quotient APTT XISample/APTT XINormal is below the predetermined reference value.
6 more elements
A test kit for use in a method for excluding anticoagulants from the group of factor XIa inhibitors in a patient sample, the test kit comprising:
- a) a factor XI-deficient plasma, and
- b) at least one neutralizing substance which neutralizes an anticoagulant other than an anticoagulant from the group of factor XIa inhibitors.
Dependencies are inferred from the claim text.